02:16 , Apr 5, 2019 |  BC Innovations  |  Targets & Mechanisms

Breaking up Hippo to tame proliferation

Drug developers are creating a new class of compounds that disrupt a protein-protein interaction in the Hippo pathway that goes awry in cancers and fibrotic diseases. At least two programs are poised to enter the...
02:03 , Feb 23, 2019 |  BioCentury  |  Product Development

Benchmarks for NASH

Benchmarking clinical value in NASH will require more than the topline data reported this week by Intercept Pharmaceuticals Inc. The readout gained Ocaliva obeticholic acid the title of first NASH therapy to meet in Phase...
16:58 , Feb 22, 2019 |  BC Week In Review  |  Clinical News

Inventiva discontinues lanifibranor for systemic sclerosis

Inventiva S.A. (Euronext:IVA) discontinued development of lanifibranor (IVA337) to treat diffuse cutaneous systemic sclerosis after the product missed the primary endpoint in the Phase II FASST trial. The next-generation PPARα, PPARδ and PPARγ agonist failed...
22:04 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Mouse studies suggest PPARα agonists could enhance the efficacy of adoptive T cell therapies for melanoma. In a mouse model of melanoma, adoptive transfer of CD8 + T cells pretreated with a tool...
18:24 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Genfit's elafibranor meets in Phase II for primary biliary cholangitis

Genfit S.A. (Euronext:GNFT) said both doses of elafibranor (GFT505) met the primary endpoint in a Phase II trial to treat primary biliary cholangitis (PBC). The company said it believes the strength of the data qualify...
18:43 , Dec 5, 2018 |  BC Extra  |  Politics & Policy

FDA NASH guidance charts course for surrogate endpoints tied to biopsies

Four companies with products in Phase III testing to treat non-alcoholic steatohepatitis are well positioned to meet endpoints that could support accelerated approval, according to requirements outlined in new FDA draft guidance. However, the guidance...
19:20 , Nov 19, 2018 |  BC Extra  |  Financial News

NASH company Genfit planning U.S. listing

As it prepares for a readout from a Phase III study of its lead candidate to treat non-alcoholic steatohepatitis, French bellwether Genfit S.A. (Euronext:GNFT) intends to conduct a listing on a U.S. exchange. Genfit said...
22:55 , Nov 15, 2018 |  BC Innovations  |  Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
00:39 , Nov 14, 2018 |  BC Extra  |  Preclinical News

Tempest data provide POC for PPAR alpha’s role in cancer

New data from immuno-oncology company Tempest Therapeutics Inc. (San Francisco, Calif.) provide preclinical proof of concept that the established cardiovascular disease target PPARα also plays a role in cancer. At last week's Society for Cancer...
02:27 , Nov 3, 2018 |  BioCentury  |  Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...